L-lysine hydrochloride is an essential amino acid for humans with various benefits including treating herpes, increasing calcium absorption, reducing diabetes-related illnesses and improving gut health.

Product information

CAS Number: 657-27-2

Molecular Weight: 182.65

Formula: C6H15ClN2O2

Chemical Name: (2S)-2,6-diaminohexanoic acid; chlorohydrogen

Smiles: Cl.NCCCC[C@H](N)C(O)=O

InChiKey: BVHLGVCQOALMSV-JEDNCBNOSA-N

InChi: InChI=1S/C6H14N2O2.ClH/c7-4-2-1-3-5(8)6(9)10;/h5H,1-4,7-8H2,(H,9,10);1H/t5-;/m0./s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : < 1 mg/mL (insoluble or slightly soluble). H2O : 100 mg/mL (547.50 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vivo:

L-lysine treatment attenuates pancreatic tissue injury induced by L-arginine by inhibiting the release of the inflammatory cytokine IL-6 and enhances antioxidant activity. Pre- or post-treatment with L-lysine leads to significant decreases in the levels of malondialdehyde and nitric oxide, while significant enhancement is observed in the activities of antioxidant enzymes (superoxide dismutase, catalase, and glutathione peroxidase) and glutathione. L-lysine supplementation almost completely ameliorates vascular calcification. Dietary L-lysine strongly suppresses plasma intact parathyroid hormone in adenine rats and supports a proper bone-vascular axis. The conserved orientation of the femoral apatite in group Lys also evidences the bone-protective effects of L-lysine. Dietary L-lysine elevates plasma alanine, proline, arginine, and homoarginine but not lysine. The dose-dependent delay in gastric emptying observed in rats is confirmed in humans with an increase in halftime of gastric emptying of 4 min/g L-lysine. Moreover, a dose-dependent increase in intestinal fluid accumulation is observed (0.4 mL/min/g L-lysine).

Products are for research use only. Not for human use.